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Faecalibacterium prausnitzii and its supernatant showed protective effects in different
chemically-induced colitis models in mice. Recently, we described 7 peptides found in
the F. prausnitzii supernatant, all belonging to a protein called Microbial Anti-inflammatory
Molecule (MAM). These peptides were able to inhibit NF-κB pathway in vitro and showed
anti-inflammatory properties in vivo in a DiNitroBenzene Sulfate (DNBS)-induced colitis
model. In this current proof we tested MAM effect on NF-κB pathway in vivo, using a
transgenic model of mice producing luciferase under the control of NF-κB promoter.
Moreover, we tested this protein on Dextran Sodium Sulfate (DSS)-induced colitis in
mice. To study the effect of MAM we orally administered to the mice a Lactococcus lactis
strain carrying a plasmid containing the cDNA of MAM under the control of a eukaryotic
promoter. L. lactis delivered plasmids in epithelial cells of the intestinal membrane allowing
thus the production of MAM directly by host. We showed that MAM administration
inhibits NF-κB pathway in vivo. We confirmed the anti-inflammatory properties of MAM in
DNBS-induced colitis but also in DSS model. In DSS model MAM was able to inhibit Th1
and Th17 immune response while in DNBS model MAM reduced Th1, Th2, and Th17
immune response and increased TGFβ production.
Keywords: Faecalibacterium prausnitzii, inflammation, colitis models, MAM (Microbial Anti-inflammatory
Molecule), Lactococcus lactis, NF-κB
INTRODUCTION
Intestinal microbiota homeostasis contributes to the protective mechanism of intestinal mucosa
against the development of chronic inflammation. In mice, some commensal bacteria such as
segmented filamentous bacteria (Gaboriau-Routhiau et al., 2009; Ivanov et al., 2009), Bacteroides
fragilis (Round and Mazmanian, 2017) and Clostridia members as Faecalibacterium prausnitzii are
able to shape gut immune responses (Sokol et al., 2008; Atarashi et al., 2013). The F. prausnitzii
bacterium accounts for 3–5% of total fecal bacteria and is one of the predominant bacterial groups
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in human feces. Decreased gut levels of F. prausnitzii can result in
reduced capacity of self-defense against inflammatory reactions.
This protective mechanism may involve the inhibition of pro-
inflammatory cytokines and stimulation of anti-inflammatory
cytokines secretion by active molecules (Zhang et al., 2014;
Quévrain et al., 2016a). One of the mechanisms used by
F. prausnitzii to inhibit the inflammation is the secretion of
bioactive molecules that are able to block nuclear factor kB
(NF-κB) activation (Sokol et al., 2008).We recently demonstrated
the NF-κB blockage by a bioactive molecule, named Microbial
Anti-inflammatory Molecule (MAM), from F. prausnitzii in
epithelial cells culture (Quévrain et al., 2016a). Years of studies
demonstrated some others bioactive molecules able to reduce
intestinal inflammation. For example, there are two proteins
secreted by Lactobacillus rhamnosus GG, p75, and p40, which
are able to inhibit epithelial cells apoptosis induced by pro-
inflammatory cytokines (Yan et al., 2007). In other hand,
one of the best characterized bioactive molecule produced by
commensal bacteria is Polysaccharide A (PSA) from B. fragilis,
a commensal bacterium exhibiting anti-inflammatory properties
(Mazmanian et al., 2005, 2008). PSA, which can be found at the
surface of vesicles secreted by B. fragilis, induce the conversion
of CD4 (+) T cells into Foxp3 (+) Treg cells reducing thus
the intestinal inflammation (Round and Mazmanian, 2017).
These findings highlighted that the searching for such bioactive
molecules remains challenging scientifically but could open the
door to innovative therapeutic strategies.
Since we described that the loss of F. prausnitzii is predictive
of Crohn’s Disease (CD) relapse after surgery (Sokol et al., 2008)
lots of progresses have been made in the comprehension of
F. prausnitzii role and mechanisms of action (Miquel et al.,
2013). Inflammatory Bowel Diseases (IBD), CD and Ulcerative
Colitis (UC), remains big issues for public health because
only suspensive treatment are available. F. prausnitzii and its
supernatant showed protective effects in various chemically-
induced colitis models in mice (Sokol et al., 2008; Martín
et al., 2014, 2015). Recently, we showed that MAM has anti-
inflammatory properties in vivo in a DNBS-induced colitis model
(Quévrain et al., 2016a). In order to do so, we used a food grade
bacterium, Lactococcus lactis, modified to contain a plasmid with
an expression cassette carrying the cDNA coding for MAM
under the control of a eukaryotic promoter (pCMV). We have
demonstrated that such recombinant L. lactis strains are able to
transfer fully functional plasmids to eukaryotic cells in vitro and
in vivo resulting in production of protein of interest by the host
(Chatel et al., 2008; Del Carmen et al., 2013; Aubry et al., 2015;
Souza et al., 2016). In vitro, the percentage of cells expressing
GFP after co-incubation with L. lactis carrying GFP cDNA could
reach 1% (Innocentin et al., 2009). As described with MAM or
GFP, plasmid transfer occurred in small intestine but also in colon
(Almeida et al., 2014; Quévrain et al., 2016a). The number of
enterocytes transfected was two times more in colon than small
intestine (Almeida et al., 2014) but we have shown recently that
plasmid transfer targeted also 5% of the DCs in small intestine or
colon (Michon et al., 2015).
Here we wanted to go further in the description of
the anti-inflammatory properties of MAM. In order to
do so, we used a transgenic mice model where luciferase
expression is under the control of NF-κB promoter to test
the inhibitory effect of MAM on NF-κB pathway in vivo. We
also characterized the effect of MAM on DSS-induced colitis
model.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Lactococcus lactis MG1363 containing pILEMPTY (LL-
pILEMPTY) plasmid and L. lactisMG1363 containing pILMAM
plasmid (LL-pILMAM) (Quévrain et al., 2016a) were grown
in M17 medium (Difco) supplemented with 1% glucose and
erythromycin (10 µg/mL) at 30◦C without agitation overnight.
The next day, the cultures were diluted 1/20 in M17 medium and
grown up at 30◦C without agitation. Based in our knowledge,
at OD = 1 the bacteria concentration is around 5 × 108
CFU/mL. Mice were gavaged with 5 × 109 CFU/mouse. For all
gavages, aliquots 1OX concentrate were previously prepared as
described and frozen at −80◦C. To use, aliquots were gradually
taw on ice bath to preserve all structures and diluted with
PBS.
Mice Experiment
This study was carried out in accordance with the guidelines of
the local ethics committee. Housing conditions and procedures
were specified by the French Law regarding the protection
of laboratory animals (authorization #78–149 of the French
Veterinary Services). Sets of 6-week-old C57BL/6J mice (n = 8
per group) (Janvier, France) were housed in groups of 4 mice
per plastic cage, under standard environmental conditions with
free access to food and water in the Animal Facility of National
Institute of Agronomic Research.
DNBS-Induced Colitis
Colitis was induced in mice under light anesthesia by a single
intra-rectal instillation of DNBS (100 mg. kg−1 of body weight)
diluted in 30% ethanol. During all long experiment, from 7
days before the DNBS (MPBio) instillation to the sacrifice
of the mice, mice were fed daily by intragastric gavage with
recombinant strains (LL-pILEMPTY and LL-pILMAM 5 × 109
CFU/200µL/mouse) or with PBS.
Mice were monitored daily for weight loss. Mice were
sacrificed at day 4, the abdomen was opened by midline incision
and the descending colon and Mesenteric Lymphatic Node
(MLN) were removed. MLN were stocked in RPMI medium on
ice and after mashed and cells counting to stimulate with anti-
CD3 and anti-CD28 for 48 h in 37◦C and 5% CO2. Colon was
rinsed in PBS, opened along the anti-mesenteric border, cleaned
and cut for cytokines assays.
DSS-Induced Colitis
Colitis was induced in mice by oral administration of 2.5%
(w/v) of Dextran Sulfate Sodium Salt (DSS) at 36,000–50,000 of
molecular weight (MPBio) dissolved in drinking water from day
0 to day 7. During all long experiment, from 7 days before the
DSS administration to the sacrifice day (D14), mice were fed by
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intragastric gavage with recombinant strains (LL-pILEMPTY and
LL-pILMAM–5× 109 CFU/200 µL/mouse) or with PBS.
Mice were monitored daily for weight loss, stool consistency,
and fecal occult blood (Hemoccult, Beckman Coulter). Disease
Activity Index (DAI) has been calculated according to the
protocol by Cooper et al. (1993). The mice were sacrificed
at day 14 and MLN and colon were collected as described
above.
Protein Extraction in Colon
One centimeter of colonic tissue was mashed by GentleMaxTM
(Miltenyl Biotec) in 1 mL of PBS plus anti-protease (Roche). The
lysate was centrifuged and the supernatant as used to measure
cytokine level by ELISA (Mabtech). The cytokines tested were
Th1- related cytokine (IFNγ and IL12); Th2-related cytokines
(IL4 and IL5); Th17-related cytokine (IL17) and Treg–related
cytokines (IL10 and TGFβ), Th22- related cytokine (IL22) and
IL6 (NF-κB pathway).
Interleukin Secretion by Stimulated
Lymphocytes
Mesenteric Lymph Nodes (MLN) isolated from mice were
mashed and filtered (70 µm, BD biosciences). Lymphocytes
were counted by flow cytometry (Accuri C6) and suspended
in RPMI (Lonza) with 100 Unit of Streptomycin, Penicillin,
PAA Laboratories and 10% Fetal Calf Serum (FCS) (Lonza)
at a concentration of 2,5.106 cells/mL in 24 wells plate
(Costar) pre-incubated with anti-CD3 and anti-CD28 antibodies,
4 µg/mL of each antibody (eBioscience) in PBS with 0.5%
FCS. Plates were incubated 48 h at 37◦C, 5% of CO2
and cytokine level was assessed by ELISA (Mabtech). The
cytokines tested were Th1- related cytokine (IFNγ); Th2-
related cytokines (IL5); Th17-related cytokine (IL17) and Treg–
related cytokines (IL10 and TGFβ) and Th22- related cytokine
(IL22).
IVIS (Analysis In vivo)
NF-κB-luciferase mice, transgenic mice model where luciferase
expression is under the control of NF-κB promoter, were used
to test the effect of MAM on NF-κB pathway in vivo. Mice were
anesthetized with a cocktail of 0.1% ketamine (Imalgene 1000,
Merial, France) and 0.06% xylazine (Rompun, Alcyon, France)
and luciferine 15 mg/mL were administrated by intraperitoneal
injection (50 µl). The luminescence of NF-κB recombinant
mice was evaluated by IVIS (In vivo Imaging System) 200
(Perkin Elmer) at D2 and D4 after DNBS challenge. Region
of interest (ROI) measurements were accessed by photon
quantification.
Statistical Analysis
All statistics and graphics have been performed on Prism-
GraphPad R©. Results represent means ± s.e.m. Statistical
significance was determined by the Mann-Whitney test. It has
been considered that ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
RESULTS
MAM Shows a Protective Effect on
DNBS-Induced Colitis by Decreasing
NF-κB Activation and Increasing
Regulatory and Repairing Pathways
Colitis was induced in NF-κB-luciferase mice treated or not
with LL-pILMAM or LL-pILEMPTY. NF-κB activation was
monitored directly on live animals using IVIS. At D4, the
luminescence was lower in DNBS- induced colitis mice treated
with LL-pILMAM than in LL-pILEMPTY or control mice (PBS).
Moreover, the NF-κB signal didn’t increase from D2 to D4 in
LL-pILMAM treated mice while it increased for LL-pILEMPTY
and control mice. This result suggests a protective effect by LL-
pILMAM compared with the other groups by inhibiting NF-κB
pathway. The region of interest (ROI) measurement confirms
these evidences (Figure 1).
Pro and anti-inflammatory cytokines secreted by lymphocytes
from MLN were monitored 4 days after DNBS administration.
As shown in Figure 2, a significant decrease in IL17, IFNγ and
IL5 was found in supernatant of lymphocytes from LL-pILMAM
treated mice compared to LL-pILEMPTY and control mice.
The concentration of IL10 was significantly increased in LL-
pILMAMmice compared to LL-pILEMPTYmice, but there is no
statistically significant difference compared to control animals.
However, no differences in TGFβ and IL22 concentrations were
observed among these groups of mice (Figure 2).
In parallel, proteins were extracted from colon tissue and
cytokines concentrations were assayed. We observed a strong
increase of TGFβ in LL-pILMAM treated mice compared to
LL-pILEMPTY and control mice. Moreover, the IL5 and IL17
cytokine levels decreased in LL-pILMAM and control mice
compared to LL-pILEMPTY mice (Figure 3). We could not
observe any differences in IL4 and IL10 production among all
groups of mice. It has to be noticed that treatment with LL-
pILEMPTY induced an increase of IL5, IL17 and IFNγ compared
to control mice.
Mam Protects Mice from DSS-Induced
Colitis
To determine the impact of local production of MAM on
another chemically-induced colitis model, we performed a DSS-
induced colitis model on mice orally administered with LL-
pILMAM or LL-pILEMPTY or PBS. Recombinant bacteria were
administered 7 days before, during and after colitis induction.
We did not observe any difference in the weight loss among
these groups of mice (Figure 4A). Oral administration of LL-
pILMAM decreased the DAI at D5 compared to pILEMPTY
or control mice. At D8 and D9 the DAI difference was only
significant compared to pILEMPTY treated mice. At this stage of
the colitis daily administration of bacteria seems to increase the
DAI (Figure 4B). The effect ofMAM is particularly significant on
bleeding (Figure 4C).
After 7 days of inflammation followed by 5 days of recovery,
MLN and colon tissues were removed and immune response
was analyzed. In MLN supernatant, INFγ and IL17 were both
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FIGURE 1 | Inhibition of NF-κB pathway in vivo after LL-pILMAM administration. NF-κB luciferase mice, transgenic mice expressing luciferase under the
control of NF-κB, were orally administered with PBS, LL-pILEMPTY or LL-pILMAM 7 days before DNBS intrarectal injection (D0) and until sacrifice (D4). NF-κB
activation was monitored by luminescence in vivo on whole animal using IVIS Spectrum. ROI (Regions of interest) measurements were used to determinate how many
photons are radiating from the source.
FIGURE 2 | Cytokines secreted by reactivated lymphocytes from MLN in a DNBS-induced colitis model. NF-κB luciferase mice were orally administered
with PBS, LL-pILEMPTY or LL-pILMAM 7 days before DNBS intrarectal injection (D0) and until sacrifice (D4). At D4 MLN were withdrawn and isolated lymphocytes
reactivated by anti-CD3/anti-CD28 antibodies. Cytokine concentration in medium was monitored 48 h after reactivation by ELISA. *P < 0.05.
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FIGURE 3 | Cytokines produced by colon tissue in DNBS-induced colitis model. NF-κB luciferase mice were orally administered with PBS, LL-pILEMPTY or
LL-pILMAM 7 days before DNBS intrarectal injection (D0) and until sacrifice (D4). At D4 colon was withdrawn and proteins extracted. Cytokine concentration in protein
extracts was monitored by ELISA. *P < 0.05, **P < 0.01.
FIGURE 4 | Effect of MAM on macroscopic scores in a DSS-induced colitis model. Mice were orally administered with LL-pILMAM, LL-pILEMPTY or PBS 7
days before and during colitis induction. Colitis was induced by adding DSS in drinking water during 7 days (D0-D7). Then DSS was removed from drinking water and
mice allowed to recover during 5 days (D7-D12). Weight (A) and DAI (B) including bleeding (C) were monitored daily. *P < 0.05.
decreased in LL-pILMAM group compared with LL-pILEMPTY
(Figure 5) as observed previously in DNBS experiment. TGFβ
was also decreased whereas no differences in IL5 and IL10
concentrations were observed among the mice groups. In
proteins extracts from colon tissues we could observe only a
decrease of IL-6 in LL-pILMAM compared with the other groups
(Figure 6). No differences in IFNγ, IL-10, IL-12, TGFβ, and IL-22
concentrations were monitored among the mice groups.
Frontiers in Microbiology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 114
Breyner et al. MAM Protective Effect on Colitis
FIGURE 5 | Cytokines secreted by reactivated lymphocytes from MLN in DSS-induced colitis model. Mice were orally administered with LL-pILMAM,
LL-pILEMPTY or PBS 7 days before and during colitis induction. Colitis was induced by adding DSS in drinking water during 7 days (D0-D7). Then DSS was removed
from drinking water and mice allowed to recover during 5 days (D7-D12). At D12 mice were killed, MLN withdrawn, cells were isolated and lymphocytes reactivated
with antiCD3/anti-CD28 antibodies. Cytokine concentration in medium was monitored 48 h after reactivation by ELISA. *P < 0.05, **P < 0.01.
FIGURE 6 | Cytokines produced by colon tissue in DSS-induced colitis model. Mice were orally administered with LL-pILMAM, LL-pILEMPTY or PBS 7 days
before and during colitis induction. Colitis was induced by adding DSS in drinking water during 7 days (D0-D7). Then DSS was removed from drinking water and mice
allowed to recover during 5 days (D7-D12). At D12 mice were killed, colon was withdrawn and proteins extracted. Cytokine concentration in protein extracts was
monitored by ELISA. **P < 0.01, ***P < 0.001.
DISCUSSION
Anti-inflammatory properties of MAM have been characterized
by an inhibition of NF-κB in vitro and a protective effect
in DNBS-induced colitis model on weight loss, macroscopic
score and a decrease in IL-17A and IFNγ secreted by
activated lymphocytes from MLN (Quévrain et al., 2016a).
Here we showed for the first time that MAM inhibits NF-κB
pathway in vivo by using NF-κB-luciferase transgenic mice.
Ours results clearly indicated that delivery of MAM cDNA
Frontiers in Microbiology | www.frontiersin.org 6 February 2017 | Volume 8 | Article 114
Breyner et al. MAM Protective Effect on Colitis
at intestinal mucosa decreased NF-κB pathway activated by
DNBS.
In DSS-induced colitis model, MAM administration didn’t
modify the weight loss significantly like in DNBS-induced colitis
model (Quévrain et al., 2016a) but showed a positive effect on
Disease Activity Index (DAI) at several days and especially on
bleeding. DAI, which is one of the main macroscopic markers,
is established by summing different scores, bleeding, stool
consistency, and weight loss reflecting the global physiological
state of the digestive tract. These results suggest that MAM is
probably able to restore tissue integrity but the mechanism is
unclear as IL22, a cytokine involved in tissue repair is slightly
decreased. It has to be noticed that this difference is significant
considering only pILEMPTY group and not the control PBS
group.
We wanted also to characterize more precisely the
mechanisms of action of MAM by going deeper in the
immune response description and by using a DSS-induced colitis
model, both models being commonly used and having different
characteristics. Despite the shortcomings, DNBS model is often
described to be a good model of CD mainly driven by Th1 and
Th17 biased-immune response but also very useful to study the
role of adaptive immune response in IBD (Kiesler et al., 2015).
One of the other main chemical used to induce colitis models
is DSS. DSS model has been described to be closer to UC with
a Th2 exacerbated immune response. But DSS inflammation is
also mainly driven by innate immune response (Chassaing et al.,
2014).
First we confirmed our results by showing that IL-17A (Th17)
and IFNγ (Th1) are decreased in MLN from LL-pILMAM group
in DNBS-induced colitis. Suppression of Th1 and Th17 cytokine
is correlated with beneficial anti-colitis effect (Reyes et al., 2016).
We could observe also a decrease of IL-5 and an increase of IL-10
both Th2 cytokines. It has to be noticed that these differences are
only significant regarding LL-pILEMPTY group. In DSS model,
MAM decreased by 2-fold IL17 secreted by reactivated MLN
lymphocytes as in DNBS model. IFNγ is also reduced but less
than in DNBS. Surprisingly, TGFβ and IL22 secretion was lower
in MAM treated group than in pILEMPTY or PBS group. Thus,
MAM has a robust inhibition effect on IL17 and IFNγ secretion
in MLN in both models.
We enlarged our investigation field and looked for the
cytokines production in colon. In DNBS model, we observed
that, like with MLN, IL17, and IL5 are reduced in colon but
only regarding pILEMPTY. More striking, we found that TGFβ,
which is involved in Treg development, is increased by MAM in
colon tissue. In healthy conditions, Treg cells play an important
role in controlling immune homeostasis. In IBD, Th1, and Th17
responses overwhelm the control mechanisms of Treg cells.
This imbalance in the intestinal immunity of IBD patients,
shifting toward the pro-inflammatory side, leads to intestinal
inflammation. In DSS model, we observed only a decrease in IL6
production in the colon from mice treated with MAM. Nuclear
factor-kB participates in controlling the activation of various
pro-inflammatory cytokine genes such as IL6, IFNγ or IL17
suggesting that NF-κB pathway is also turned off inMAM treated
mice in DSS colitis model.
As noticed above we observed particularly in DNBS-induced
colitis an increase of IL-5, IL-17 and IFNγ in colon tissue of
mice treated with LL-pILEMPTY compared to control group
and a tendency to decrease IL10 even if the difference is not
statistically significant. This profile of response describes L. lactis
as a pro-inflammatory bacterium. This is in accordance with
previous results where we showed that L. lactis co-incubated
with PBMC give a very low IL10/IL12 ratio (Sokol et al., 2008;
Kechaou et al., 2013) or a slight increase of IL-8 secreted by HT-
29 after TNFα activation (Kechaou et al., 2013). These two criteria
are characteristic of a pro-inflammatory strain. Nevertheless,
this slight pro-inflammatory effect of our bacterial vector didn’t
counterbalance the anti-inflammatory properties of MAM as we
have less weight loss or a macroscopic score lower in MAM
treated group compared to pILEMPTY treated group (Quévrain
et al., 2016a).
Our strategy of plasmid transfer results in MAM expression
by epithelial cells. We have no proof that MAM or its peptides
produced naturally by F. prausnitzii (Quévrain et al., 2016b)
have to enter inside the cells of the intestinal membrane to
show their protective effect. We tried to produce MAM or its
peptides by heterologous protein production or by chemical
synthesis without success (Quévrain et al., 2016a). Nevertheless,
our strategy of producing MAM by epithelial cell mimics the
results obtained with F. prausnitzii or its supernatant containing
MAM as inhibition of NF-kB, protection against weight loss,
increase of IL10 (Sokol et al., 2008), decrease of IL17 (Zhang et al.,
2014), decrease of IL6 or IFNγ (Martín et al., 2014) validating our
approach.
Our observations suggest that MAM was able to decrease
Th1 and Th17 pro-inflammatory cytokines in MLN and colon
tissue in both DNBS and DSS colitis model and to enhance
TGFβ in DNBS model promoting thus host protective effect
and attenuating intestinal inflammation through mechanisms
affecting NF-κB activation. Nevertheless, MAM was not able to
decrease the Th2 immune response, typically induced in DSS
colitis, which results in a less effective protection.
These results can be considered as a new step in the
characterization of MAM mechanism of action opening thus the
development of innovative therapeutic strategies based on the
use of this bioactive molecule. The challenge is to define the
immunological regulation associated with this protein or part of
this, the location of this protein and the vector used to deliver
able to suppress inflammation and determine the optimal means
to translate this knowledge to the treatment of inflammatory
disease.
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